ATRC Aurigon Toxicology Center Ltd. (ATRC) is the research facility of the Aurigon Group, which was established in 2000 as an independent, privately-owned contract research institute dedicated to preclinical services for human and veterinary pharmaceuticals, food and chemicals. ATRC has more than 65 highly educated staff members with experience up to 3 decades in non-clinical research and drug development. ATRC provides a full range of advisory and experimental services in pharmacology, bio-/analytics and toxicology. Ranging from early-phase product efficacy and safety evaluation to regulatory toxicology and late-stage pre-marketing testing, we cover all areas of non-clinical drug development. ATRC operates state-of-the-art GLP- and/or GMP-compliant facilities in Dunakeszi (north border of Budapest) and in Budapest itself.
Main roles in project
ATRC will provide the relevant non-clinical GLP studies and assays for the non-clinical safety evaluation of the selected Traspain vaccine candidate (with and without CDA adjuvant) in the required rodent or non-rodent species, which are needed for the IND/CTA to support the clinical translation. As a final deliverable, a complete non-clinical toxicological evaluation of the different vaccine doses in the selected species will be presented in a study report.
This project has received funding from the European Union’s Horizon 2020 research and innovationprogramme under grant agreement No 815418.